- Tesaro's (TSRO) drug niraparib significantly improved progression-free survival for patients with ovarian cancer in both cohorts of the phase 3 NOVA trial

- The NOVA trial successfully achieved its primary endpoint of PFS in the germline BRCA mutant cohort  

- The NOVA trial successfully achieved its primary endpoint of PFS in the germline and non-germline BRCA mutant cohort. PFS endpoint is also achieved in both thehomologous recombination deficient (HRD)-positive and overall analysis populations

- NOVA is the first successful prospectively designed Phase 3 trial of a PARP . . .